Table 2 Comparison of several factors for patients who were divided by the response to first-line GP chemotherapy
Good (n = 30) | Poor (n = 15) | P | |
|---|---|---|---|
Age, median (year, range) | 64.0 (58.5–73.0) | 66.0 (64.0–71.0) | 0.289 |
Type of platinum compound used as the first-line | 0.695 | ||
Cisplatin | 23 (76.7 %) | 13 (86.7 %) | |
Carboplatin | 7 (23.3 %) | 2 (13.3 %) | |
Response to the first-line GP chemotherapy | - | ||
CR | 11 (36.7 %) | - | |
PR | 19 (63.3 %) | - | |
SD | - | 5 (33.3 %) | |
PD | - | 10 (66.6 %) | |
TTP of the first-line GP chemotherapy, median (months, range) | 11.6 (7.8–14.2) | 3.13 (2.2–5.0) | <0.001 |
Cycles of the first-line GP chemotherapy, median (range) | 6.0 (6.0–7.3) | 4.0 (3.0–4.0) | <0.001 |
TFI between GP and MVAC, median (months, range) | 2.5 (0.7–9.9) | 1.7 (0.6–3.4) | 0.202 |
Primary tumor site | >0.999 | ||
Bladder | 20 (66.7 %) | 10 (66.7 %) | |
Ureter or renal pelvic | 4 (13.3 %) | 2 (13.3 %) | |
Ureter or renal pelvic with bladder | 6 (20.0 %) | 3 (20.0 %) | |
Clinical N stage | 0.453 | ||
N0 | 4 (13.3 %) | 2 (13.3 %) | |
N1 | 5 (16.7 %) | 3 (20.0 %) | |
N2 | 11 (36.7 %) | 8 (53.3 %) | |
N3 | 10 (33.3 %) | 2 (13.3 %) | |
Distant metastatic site at the time of MVAC administration | |||
Lung | 15 (50.0 %) | 6 (40.0 %) | 0.752 |
Bone | 10 (33.3 %) | 6 (40.0 %) | 0.746 |
Liver | 8 (26.7 %) | 1 (6.7 %) | 0.234 |
Others | 4 (13.3 %) | - (0.0 %) | 0.285 |
Hemoglobin (g/dL, range) | 11.3 (10.5–11.9) | 11.0 (9.8–11.3) | 0.032 |
Absolute neutrophil count (/dL, range) | 3751.5 (2733.0–5337.0) | 3524.0 (2415.0–5252.0) | 0.596 |
Platelet count, 103(/dL, range) | 219.5 (184.8–291.5) | 216.0 (169.0–311.0) | 0.952 |
eGFR (ml/min, range) | 62.6 (52.6–75.3) | 71.5 (47.0–84.7) | 0.739 |
Serum bilirubin (mg/dL, range) | 0.4 (0.3–0.6) | 0.3 (0.3–0.4) | 0.047 |
Serum albumin (g/dL, range) | 4.0 (3.8–4.4) | 3.8 (3.5–4.2) | 0.159 |
ECOG performance status (PS) | 0.275 | ||
PS 0 | 12 (40.0 %) | 8 (53.3 %) | |
PS 1 | 16 (53.3 %) | 7 (46.7 %) | |
PS 2 | 2 (6.7 %) | - (0.0 %) | |